<DOC>
	<DOCNO>NCT01215565</DOCNO>
	<brief_summary>The purpose study evaluate antitumor activity sunitinib patient advanced/inoperable fibrolamellar hepatocellular carcinoma . Rationale : Sunitinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor</brief_summary>
	<brief_title>Study Sunitinib Patients With Advanced/Inoperable Fibrolamellar Carcinoma</brief_title>
	<detailed_description>Fibrolamellar hepatocellular carcinoma variant rare hepatocellular carcinoma witch distinct clinical , histological prognostic feature conventional hepatocellular carcinoma . This entity typically occur young adult underlie hepatitis cirrhosis . Surgical resection could propose referral center case localize tumor . However , case postoperative recurrence , `` salvage '' resection often possible . Overall prognosis remain poor , primary chemoresistance early recurrence metastasis . Sunitinib ( SUTENT ) potent tyrosine kinase inhibitor , double antiangiogenic antitumor activity , target multiple receptor VEGF-R , PDGF-R , KIT FLT3 . Since 2006 , Sunitinib approve treat advanced kidney cancer also call advanced renal cell carcinoma ( typically chemoresistant disease active treatment available ) . Several target sunitinib overexpressed hepatocellular carcinoma line show Literature review pathological study . Otherwise , overexpression PDGFR VEGFR correlate recurrence invasion HCC . Finally , sunitinib show interesting antitumor activity patient conventional advanced HCC . Thereby , seem important study well sunitinib , potent antitumor antiangiogenic agent , work treat patient advance inoperable fibrolamellar hepatocellular carcinoma especially , set lack effective therapy . Furthermore , seem urgent conduct translational research assessment identify predictive biomarkers response . In study , orally sunitinib dosed 50 mg daily administrate patient 4 week , follow 2 week wash . This administration schedule base phase I study sunitinib .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Angiogenesis Modulating Agents</mesh_term>
	<criteria>Fibrolamellar hepatocellular carcinoma histopathologically proven Inoperable/advanced ( Tumor recurrence inoperable metastatic surgical indication ) . Available Tumor tissue analysis ( biopsy surgical specimen ) Performance status WHO ≤ 2 . Adequate organ function : Hematology ( absolute neutrophil count equal superior 1,5 x 10*9/l , platelet equal superior 100 x 10*9/l ) , clearance creatinine &gt; 60 ml/min ) , AST/ALT ≤ 5 N , PAL ≤ 5 N , total bilirubin ≤ 2N . Hypersensitivity sunitinib . Contraindication sunitinib , include uncontrolled hypertension , medical history cerebrovascular accident , unstable cardiac pathology despite optimal medical therapy ( myocardial infarction within 6 month prior study drug administration , severe/unstable angina ) , active hemorrhagic syndrome concomitant treatment anticoagulant . Any severe acute chronic comorbid may compromise comply study participation : uncontrolled infection , symptomatic congestive heart failure , liver disturbance , chronic renal failure , active gastroduodenal ulcer ( nonexhaustive list ) Known brain metastasis . Diagnosis second malignancy within last 3 year , except basal cell squamous cell skin cancer , situ carcinoma cervix uteri Current treatment another clinical trial . Prior treatment investigational agent within 4 week Patient i.v bisphosphonate therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Liver Neoplasms</keyword>
	<keyword>Pathologic Processes</keyword>
	<keyword>Digestive System Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Neoplasms , Glandular Epithelial</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Angiogenesis Inhibitors</keyword>
	<keyword>Angiogenesis Modulating Agents</keyword>
	<keyword>Growth Substances</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Growth Inhibitors</keyword>
</DOC>